Chinese cosmetics company known for eye-care and anti-aging skincare products under the Marubi brand.
Chinese cosmetics company known for eye-care and anti-aging skincare products under the Marubi brand.
Sells its skincare through online platforms and offline counters, with eye cream the product that built the brand and newer brands added to widen the range. It is founder-controlled.
In one line: A Chinese anti-aging/eye-care skincare brand.
Moat: narrow (brand). Recognized eye-care skincare niche brand versus larger diversified beauty competitors.
Headquarters: Guangzhou, China · Employees: 1,380
Size Guangdong Marubi Biotechnology (603983.SS) is a China Consumer Staples company (Household/Personal Care) with a market value of $1.62B, the 1411th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥27.15 on 18 Nov 2026.
Performance Over six months the shares gained 9.3%, against +3.4% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 6.5% over the last twelve months (peer median +7.6%); the operating margin is 1.8% (peer median 9.9%).
Valuation It trades at 45.5× forward earnings against a peer median of 18.9× (2nd most expensive of 21).
Capital Return on invested capital runs 3.7 points below its cost of capital (7.6% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.24B | CN¥3.44B | CN¥2.95B | CN¥2.21B | CN¥1.71B |
| Revenue growth | — | +17% | +34% | +29% | — |
| Gross profit | CN¥2.41B | CN¥2.51B | CN¥2.16B | CN¥1.55B | CN¥1.15B |
| EBITDA | n/a | CN¥294M | CN¥369M | CN¥201M | CN¥175M |
| Net income | CN¥141M | CN¥247M | CN¥342M | CN¥259M | CN¥174M |
| Free cash flow | -CN¥62.3M | CN¥72.4M | -CN¥6.50M | CN¥115M | -CN¥57.0M |
| Capital expenditure | CN¥162M | CN¥205M | CN¥321M | CN¥260M | CN¥114M |
| Total debt | CN¥457M | CN¥398M | CN¥794M | CN¥255M | CN¥285M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guangdong Marubi Biotechnology 603983.SS | $1.62B | +9% | -6% | 2% | 45.5× | n/a |
| Proya Cosmetics 603605.SS | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% |
| Yunnan Botanee Bio-Technology 300957.SZ | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603983.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.7% | +1.1% | 9th highest of 21 |
| 6-month return | +9.3% | +3.4% | 10th highest of 21 |
| Distance from 52-week high | -24.6% | -24.5% | 11th highest of 21 |
| Revenue growth (TTM) | -6.5% | +7.6% | 3rd lowest of 21 |
| Operating margin | 1.8% | 9.9% | 2nd lowest of 21 |
| Forward P/E | 45.5× | 18.9× | 2nd most expensive of 21 |
| ROIC minus cost of capital | -3.7 pp | +6.2 pp | 3rd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| Edgewell Personal Care EPC | United States | $1.30B | +67% | -10% | 7% | 14.2× | n/a | n/a |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.17B | -42% | +23% | 8% | 14.4× | -6.1% | +21.2% |
| d'Alba Global 483650.KS | South Korea | $1.13B | -55% | +49% | 22% | 12.0× | -6.6% | +53.0% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |